Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study James Liu, M.D., Adam Allgood, Pharm.D., Leonard R. Derogatis, Ph.D., Stephen Swanson, M.D., Michael O’Mahony, M.D., Bertrand Nedoss, M.D., Herbert Soper, M.D., Edward Zbella, M.D., Svetlana Vladimirovna Prokofieva, M.D., Lisa Zipfel, M.S., Chun-Yuan Guo, M.D., Ph.D. Fertility and Sterility Volume 95, Issue 1, Pages 366-368 (January 2011) DOI: 10.1016/j.fertnstert.2010.08.005 Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions
Figure 1 Mean change from baseline (± SE) in average daily moderate-to-severe hot flash frequency by week. All treatment groups were compared with placebo group. Significant reduction was achieved by week 4 in esterified estrogens (EE) 0.30 mg + methyltestosterone (MT) 0.60 mg, week 5 in esterified estrogens 0.30 mg + methyltestosterone 0.30 mg, week 6 in esterified estrogens 0.45 mg, week 10 in esterified estrogens 0.30 mg, and no significant change at all time points in methyltestosterone 0.60 mg. LOCF = last observation carried forward. Fertility and Sterility 2011 95, 366-368DOI: (10.1016/j.fertnstert.2010.08.005) Copyright © 2011 American Society for Reproductive Medicine Terms and Conditions